Clinical Genomics Announces New Publication from Flinders Medical Centre, Highlighting the Use of COLVERA® as a Quantitative ctDNA Biomarker for Response to Colorectal Cancer Therapy
February 18, 2022 08:00 ET
|
Clinical Genomics
-- Article outlines advantages and provides further data to support the use of COLVERA for assessing response to treatment and risk of disease progression – -- Study finds that a COLVERA positive...
Clinical Genomics Announces Expansion of Medicare Coverage of COLVERA® Liquid Biopsy for Colorectal Cancer Molecular Residual Disease and Recurrence Detection
October 06, 2021 11:30 ET
|
Clinical Genomics
BRIDGEWATER, N.J., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Clinical Genomics, a provider of cancer diagnostic solutions, including liquid biopsy tests for molecular residual disease (“MRD”) and recurrence...
Clinical Genomics Announces Three Poster Presentations at ASCO 2021 Annual Meeting, Including New Data Highlighting Clinical Utility of COLVERA® Liquid Biopsy for Colorectal Cancer Recurrence Detection and Prediction of Clinical Outcomes
June 14, 2021 08:00 ET
|
Clinical Genomics
BRIDGEWATER, N.J., June 14, 2021 (GLOBE NEWSWIRE) -- Clinical Genomics, a provider of cancer diagnostic solutions, including liquid biopsy tests for minimal residual disease (“MRD”) and recurrence...
Clinical Genomics Announces Nationwide Expansion of Patient Access to COLVERA®
January 11, 2021 08:00 ET
|
Clinical Genomics
-- New York State grants permit for CLIA laboratory, expanding access to COLVERA test to patients in all 50 states -- BRIDGEWATER, N.J., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Clinical Genomics (“CG”...
Clinical Genomics Announces Medicare Coverage Applicable to COLVERA® (Liquid Biopsy Test to Detect Recurrence of Colorectal Cancer)
November 13, 2020 11:30 ET
|
Clinical Genomics
BRIDGEWATER, N.J., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Clinical Genomics (“CG” or the “Company”), a provider of cancer diagnostic solutions, including liquid biopsy tests, today announced that Novitas...
Clinical Genomics to Present at 2020 Canaccord Genuity Virtual Medical Technologies & Diagnostics Forum
November 10, 2020 16:30 ET
|
Clinical Genomics
BRIDGEWATER, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Clinical Genomics (“CG” or the “Company”), a provider of colorectal cancer diagnostic solutions, including liquid biopsy tests, today announced...
Clinical Genomics Announces Publication of Additional Clinical Data for COLVERA® Recurrence monitoring Blood Test for Colorectal Cancer Patients
September 22, 2020 08:00 ET
|
Clinical Genomics
BRIDGEWATER, N.J., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Clinical Genomics (“CG” or the “Company”), a provider of cancer diagnostic solutions, including liquid biopsy tests for recurrence monitoring of...
Clinical Genomics Announces Key Executive Appointments
July 28, 2020 08:00 ET
|
Clinical Genomics
-- Building management team to support development and commercialization of innovative liquid biopsy tests, COLVERA®, for colorectal recurrence monitoring, and TRIDENT, for colorectal screening -- ...
Clinical Genomics Announces Publication of Additional Positive Data Reinforcing Key Benefits of COLVERA®, Blood Test for the Recurrence Monitoring of Colorectal Cancer in Cancer, an American Cancer Society Journal
May 27, 2020 08:00 ET
|
Clinical Genomics
BRIDGEWATER, N.J., May 27, 2020 (GLOBE NEWSWIRE) -- Clinical Genomics (“CG” or the “Company”), a provider of cancer diagnostic solutions, including liquid biopsy tests, today announced that the...
Clinical Genomics Expands Strategic Relationship with Quest Diagnostics and Further Increases Momentum for Innovative First-Line Colorectal Cancer Screening Blood Test
April 30, 2020 11:30 ET
|
Clinical Genomics
-- Advances key development milestones for the Trident Program -- -- Further strengthens strategic alliance with Quest Diagnostics focused on the Trident Program for CRC screening -- BRIDGEWATER,...